Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
0.9930
Dollar change
-0.0670
Percentage change
-6.32
%
Index- P/E- EPS (ttm)-0.89 Insider Own1.17% Shs Outstand16.95M Perf Week-1.68%
Market Cap16.87M Forward P/E- EPS next Y-0.84 Insider Trans5.30% Shs Float16.79M Perf Month-13.65%
Income-14.20M PEG- EPS next Q-0.21 Inst Own31.29% Short Float1.00% Perf Quarter-13.65%
Sales0.65M P/S25.96 EPS this Y37.47% Inst Trans2.83% Short Ratio2.66 Perf Half Y35.10%
Book/sh0.96 P/B1.03 EPS next Y-3.72% ROA-51.96% Short Interest0.17M Perf Year-19.92%
Cash/sh1.09 P/C0.91 EPS next 5Y- ROE-93.57% 52W Range0.43 - 1.61 Perf YTD35.10%
Dividend Est.- P/FCF- EPS past 5Y39.67% ROI-62.69% 52W High-38.32% Beta0.36
Dividend TTM- Quick Ratio5.97 Sales past 5Y-0.99% Gross Margin-22.73% 52W Low133.65% ATR (14)0.07
Dividend Ex-Date- Current Ratio5.97 EPS Y/Y TTM-112.83% Oper. Margin-2426.73% RSI (14)46.37 Volatility8.97% 6.88%
Employees15 Debt/Eq0.39 Sales Y/Y TTM-51.02% Profit Margin-2181.11% Recom1.00 Target Price4.42
Option/ShortYes / Yes LT Debt/Eq0.39 EPS Q/Q78.63% Payout- Rel Volume1.39 Prev Close1.06
Sales Surprise- EPS Surprise36.00% Sales Q/Q- EarningsMay 14 AMC Avg Volume63.31K Price0.99
SMA20-2.79% SMA50-4.73% SMA20010.83% Trades Volume87,939 Change-6.32%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
May-20-24 05:25PM
May-16-24 05:45PM
May-14-24 08:56PM
04:05PM
May-02-24 04:15PM
09:53PM Loading…
Mar-06-24 09:53PM
04:05PM
Mar-01-24 07:30AM
Feb-26-24 04:15PM
Jan-18-24 08:30AM
Jan-09-24 09:05AM
Dec-12-23 08:30AM
Nov-09-23 11:06AM
Nov-08-23 05:22PM
04:05PM
04:05PM Loading…
Nov-07-23 04:05PM
Oct-26-23 04:30PM
Oct-03-23 08:30AM
Sep-12-23 01:02PM
Sep-06-23 08:30AM
Aug-22-23 05:30PM
Aug-13-23 05:33AM
Aug-11-23 06:07AM
Aug-10-23 05:30PM
04:20PM
04:05PM
Jul-27-23 04:05PM
Jul-21-23 08:00AM
Jul-18-23 08:00AM
May-10-23 06:25PM
05:18PM Loading…
05:18PM
04:05PM
May-04-23 10:00AM
May-03-23 10:00AM
Apr-27-23 04:05PM
Apr-05-23 08:30AM
Apr-04-23 12:30PM
Mar-30-23 06:15PM
04:05PM
Mar-29-23 10:13AM
Mar-21-23 04:05PM
Mar-14-23 08:30AM
Mar-01-23 08:30AM
Dec-29-22 06:02AM
Dec-27-22 08:30AM
Dec-19-22 08:17AM
Dec-08-22 08:30AM
Nov-17-22 05:17AM
Nov-14-22 05:15PM
04:01PM
Nov-03-22 08:30AM
Oct-31-22 08:30AM
Oct-27-22 08:30AM
Oct-26-22 08:30AM
Oct-25-22 04:42PM
08:30AM
Sep-06-22 04:30PM
Aug-25-22 08:30AM
Aug-11-22 05:35PM
04:01PM
08:30AM
Aug-10-22 08:30AM
Jul-28-22 04:50PM
Jul-08-22 06:28AM
May-20-22 12:49PM
May-19-22 11:56AM
08:30AM
May-16-22 08:45AM
07:30AM
May-12-22 05:35PM
May-10-22 05:35PM
08:30AM
May-09-22 07:30PM
Apr-27-22 08:00AM
Apr-25-22 08:30AM
Apr-21-22 08:30AM
Mar-31-22 04:10PM
Mar-29-22 01:08PM
Mar-10-22 05:15PM
04:01PM
Mar-03-22 04:05PM
Feb-01-22 08:30AM
Jan-31-22 04:24AM
Jan-27-22 01:38PM
08:30AM
Jan-12-22 08:30AM
Jan-10-22 08:30AM
Dec-23-21 08:05AM
Dec-15-21 08:30AM
Dec-01-21 07:12PM
Nov-23-21 05:09PM
Nov-15-21 06:45AM
06:00AM
Nov-10-21 08:30AM
Nov-02-21 06:22AM
Oct-28-21 03:06PM
Oct-21-21 09:32PM
Oct-04-21 07:30AM
Sep-10-21 03:19PM
Aug-30-21 05:10PM
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 14 '24Buy1.081,3041,404180,806Jun 14 05:19 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 13 '24Buy0.974,5704,438179,502Jun 14 05:19 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 12 '24Buy0.974,1264,013174,932Jun 14 05:19 PM
Angotti Vincent J.Chief Executive OfficerDec 13 '23Buy0.7310,0007,268101,805Dec 14 08:11 AM
Angotti Vincent J.Chief Executive OfficerSep 11 '23Buy0.8010,0007,95091,805Sep 11 07:13 PM
Palmer Pamela PChief Medical OfficerAug 25 '23Sale1.097,4428,10430,753Aug 25 04:45 PM
Palmer Pamela PChief Medical OfficerAug 24 '23Sale1.179,51411,13138,195Aug 25 04:45 PM